Grades, scores, and FDA catalyst signals for Gene Therapy stocks tracked by BiotechSign
| Ticker | Company | Score | Grade | Sector | Signals |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | 86 | A | Gene Therapy | — |
| RGNX | REGENXBIO Inc | 66 | B | Gene Therapy | — |
| RCKT | Rocket Pharmaceuticals | 65 | C | Gene Therapy | — |
| QURE | uniQure NV | 65 | C | Gene Therapy | — |
| SLDB | Solid Biosciences | 48 | D | Gene Therapy | — |
| VRTX | Vertex Pharmaceuticals | 45 | D | Gene Therapy | — |
Gene therapy companies develop one-time curative treatments that deliver functional copies of defective genes using viral vectors — primarily adeno-associated virus (AAV) — or other delivery mechanisms. The field has produced landmark approvals including Luxturna and Zolgensma, but faces persistent challenges: manufacturing complexity, high cost of goods, durability questions, and elevated dilution risk as companies require large capital raises to reach pivotal trials. PDUFA catalysts in gene therapy are among the most binary in biotech. FDA scrutiny on immunogenicity, off-target effects, and long-term safety data can delay or derail approvals. Investors should monitor clinical trial design, vector serotype choice, and manufacturing partnership strength.